Contact: Gina DiGravio, 617-358-7838, ginad@bu.edu

Boston University Secures $2.5 Million NIH Grant to Propel Cardiovascular Epidemiology Training into New Era

In a significant development for cardiovascular research and public health, Boston University’s Chobanian & Avedisian School of Medicine has been awarded a prestigious five-year T32 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). This $2.5 million grant marks the second renewal of the Multidisciplinary Training Program in Cardiovascular Epidemiology (CVE), originally launched in 2016. The program is directed by two of BU’s leading researchers: Vanessa Xanthakis, PhD, FAHA, and Mathew Nayor, MD, MPH.

Cardiovascular epidemiology sits at the intersection of clinical medicine, public health, and translational science, focusing on understanding the distribution, determinants, and preventive strategies for heart and vascular diseases in various populations. Despite advances in medicine, cardiovascular diseases remain the leading cause of mortality worldwide, accounting for approximately one-third of all global deaths. The persistence of these figures highlights the urgent need for comprehensive research and training of experts capable of addressing this public health crisis via population-level interventions and precision medicine approaches.

The T32 grant awarded to BU supports a robust, multidisciplinary two-year postdoctoral training program that equips both MD and PhD candidates with advanced skills to become tomorrow’s academic leaders and innovators in cardiovascular epidemiology. The program uniquely combines diverse training tracks including translational epidemiology and biology, translational epidemiology and implementation science, statistical genetics and genomics, as well as bioinformatics and computational biology. By integrating these cutting-edge fields, trainees acquire the expertise to analyze complex data, interpret biological mechanisms, and expedite the translation of epidemiologic discoveries into clinical and public health practice.

Dr. Vanessa Xanthakis, a distinguished biostatistician with a rigorous background in applied mathematics and statistical methodologies, has been instrumental in advancing clinical epidemiologic research through her involvement with the landmark Framingham Heart Study. Her scholarly work over the past 15 years has shed critical light on cardiac remodeling and subclinical cardiovascular disease. By leveraging sophisticated statistical models, Dr. Xanthakis elucidates novel risk factors and evaluates the prognostic value of metrics such as the American Heart Association’s concept of ideal cardiovascular health. Her research extends into vascular imaging techniques, including echocardiography and vascular testing, to decipher biological, environmental, and genetic influences on cardiac structure and function. Moreover, her leadership in the Framingham Heart Study Pathway Program enriches the educational experience of internal medicine residents, fostering early career physician-scientists dedicated to epidemiologic inquiry.

Complementing this expertise is Dr. Mathew Nayor, a clinical-translational investigator and practicing heart failure cardiologist whose research bridges fundamental science and applied clinical studies. With eight years of collaboration on community-based projects rooted in the Framingham Heart Study, Dr. Nayor explores metabolic and physiological responses to controlled interventions such as exercise regimens and dietary modifications. His scholarly contributions span a wide range—from proteomic profiling to identify biomarkers predictive of heart failure risk, to mechanistic studies probing the intricate links between metabolic health, lifestyle factors, and cardiovascular disease susceptibility. This integrative approach not only enhances understanding of disease pathophysiology but also informs the development of tailored preventive and therapeutic strategies.

The financing provided by the NIH grant will support the recruitment, mentorship, and career development of five postdoctoral scholars every two years, bolstering the pipeline of investigators trained in state-of-the-art cardiovascular epidemiology. Trainees will benefit from rich interdisciplinary collaborations, access to expansive datasets such as those from the Framingham Heart Study, and engagement with innovative methodologies including genomic analyses and advanced computational biology. Through this intensive training, Boston University aims to produce leaders capable of transforming epidemiologic data into impactful health solutions that reduce the burden of cardiovascular diseases globally.

This renewed investment underscores the importance of sustained federal funding for training programs that blend diverse scientific disciplines to confront complex health challenges like cardiovascular disease. By fostering expertise in both traditional epidemiology and emerging biomedical technologies, Boston University is positioning its trainees to spearhead breakthroughs that integrate genetic, environmental, and behavioral determinants of cardiovascular risk. Such comprehensive perspectives are imperative in designing holistic interventions that are both effective and equitable.

Moreover, the program’s emphasis on translational epidemiology bridges the gap between laboratory discoveries and real-world implementation, ensuring that scientific insights inform health policies, clinical guidelines, and community-based prevention efforts. This is particularly crucial given the evolving epidemiological landscape shaped by aging populations, changing lifestyle patterns, and disparities in health outcomes across different demographic groups.

Dr. Xanthakis and Dr. Nayor’s leadership reflects a broader trend in academic medicine where multidisciplinary collaboration and data-driven approaches are redefining cardiovascular research. Their combined expertise exemplifies how integrating biostatistics, genomics, clinical investigation, and population science fosters a fertile environment for innovation. The program’s trainees emerge not only as skilled researchers but also as changemakers equipped to influence clinical practice and public health workflows in dynamic healthcare ecosystems.

As the Multidisciplinary Training Program in Cardiovascular Epidemiology enters its next phase, it promises to be a crucible for cultivating next-generation scientists who will shape the future trajectory of cardiovascular health research. By leveraging the synergy of rigorous training, mentorship, and cutting-edge science, Boston University is reaffirming its commitment to reducing the global toll of cardiovascular disease through knowledge, discovery, and action.

For media inquiries and further information about the program, please contact Gina DiGravio at ginad@bu.edu or call 617-358-7838.

Subject of Research: Cardiovascular Epidemiology Training and Research
Article Title: Boston University Secures $2.5 Million NIH Grant to Propel Cardiovascular Epidemiology Training into New Era
News Publication Date: April 27, 2026
Web References: National Institutes of Health, National Heart, Lung, and Blood Institute; Boston University Chobanian & Avedisian School of Medicine
References: Framingham Heart Study publications, American Heart Association Reports
Image Credits: Boston University School of Medicine
Keywords: Cardiovascular Epidemiology, NIH T32 Grant, Postdoctoral Training, Biostatistics, Translational Research, Framingham Heart Study, Biomarkers, Metabolic Health, Heart Failure, Genomics, Bioinformatics

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, and aging-related changes in the vasculature play an undeniable role in this pervasive health challenge. Historically, assessing cardiovascular risk has relied heavily on traditional factors such as hypertension, cholesterol levels, and lifestyle habits. However, this novel study transcends conventional paradigms by focusing on the heterogeneity of vascular aging manifestations — including arterial stiffness, endothelial dysfunction, and microvascular rarefaction — and clustering these phenotypes to better understand their predictive efficacy.

The research team, led by van Sloten, Boutouyrie, and Abouqateb, conducted an extensive community-based cohort investigation, leveraging advanced imaging techniques combined with longitudinal clinical data to unearth underlying patterns of vascular aging. The researchers employed sophisticated multivariate statistical models and machine learning algorithms to identify natural clusters of vascular phenotypes, thereby capturing the multidimensional nature of vascular health degradation rather than relying on single biomarker assessments.

What makes this approach particularly transformative is its ability to stratify populations into subgroups based on their unique vascular aging profiles, which correlate with varying degrees of cardiovascular event risk. One cluster, characterized by pronounced arterial stiffness together with endothelial impairment, emerged as a high-risk group with significantly elevated incidence rates of myocardial infarction and stroke over the study’s follow-up period. Conversely, clusters exhibiting milder or isolated vascular changes corresponded to comparatively lower event rates.

The vascular aging manifestations that underpinned these clusters are mechanistically diverse, reflecting the complex biology of the aging vascular system. Arterial stiffness, commonly quantified by pulse wave velocity, results from structural alterations within the arterial wall, such as collagen deposition, elastin fragmentation, and smooth muscle cell dysfunction. Endothelial dysfunction, often assessed by flow-mediated dilation techniques, signals impaired vasodilatory capacity and pro-inflammatory states that predispose vessels to atherosclerosis. Microvascular changes detected via retinal imaging and capillary density measurements reveal subtle but critical impairments in tissue perfusion.

The team’s integrative analysis illuminated how these factors do not act in isolation but converge synergistically, compounding the risk. This insight advances the paradigm from a simplistic risk factor tally to a systems-level understanding of cardiovascular aging, emphasizing the need for multiparametric assessments in clinical practice. The implications for personalized medicine are profound: by identifying individuals who fall into these high-risk vascular aging clusters early, clinicians could tailor preventive strategies more effectively, targeting specific vascular dysfunction pathways rather than generic guidelines.

Furthermore, the study’s design incorporated robust longitudinal follow-up and external validation cohorts, ensuring the reproducibility and generalizability of findings. The researchers meticulously controlled for confounding factors such as demographic variables, comorbid conditions, and medication use, strengthening the evidence that vascular aging clusters independently predict cardiovascular events. By leveraging modern computational methodologies alongside state-of-the-art vascular imaging, this work bridges the gap between molecular vascular biology and epidemiological risk prediction.

The findings also subtly underscore potential therapeutic targets. For instance, interventions aimed at reducing arterial stiffness—whether through pharmacologic agents like ACE inhibitors or lifestyle modifications such as structured exercise—could profoundly shift a patient’s cluster designation and consequently their risk trajectory. Similarly, therapeutics enhancing endothelial function may be pivotal in altering disease course for certain vascular aging phenotypes identified in the clusters.

Beyond clinical implications, this research stimulates new avenues for basic science inquiry into the biological underpinnings of vascular aging clusters. Molecular profiling of individuals within each cluster could reveal distinct gene expression patterns, inflammatory mediators, and extracellular matrix remodeling factors. Such discoveries would refine our mechanistic understanding of cardiovascular aging and accelerate the development of biomarker-driven therapies.

Critically, this work drives home the notion that cardiovascular aging is not monolithic but a composite of overlapping vascular pathophysiologies. This nuanced appreciation invites a reassessment of current cardiovascular risk models, which, though robust, often fail to capture the dynamic, multifaceted nature of vascular aging. Incorporation of cluster-based vascular aging assessments in future risk calculators could enhance predictive accuracy, ultimately saving lives through earlier detection and intervention.

The study’s dissemination has sparked rapid discourse among cardiologists, gerontologists, and preventive medicine experts worldwide. Many see the cluster approach as a potential blueprint for investigating other age-related conditions characterized by heterogeneity, such as neurodegenerative diseases and metabolic syndromes. Moreover, the computational framework applied herein exemplifies the transformative potential of artificial intelligence and machine learning in medical research, turning vast complex datasets into actionable clinical insights.

While the findings are undeniably promising, some challenges remain in translating these vascular aging clusters into routine clinical practice. Standardization of measurement techniques, scaling of sophisticated imaging modalities, and integration into electronic health records will require concerted efforts across healthcare systems. Furthermore, it will be essential to validate cluster-based interventions prospectively through randomized clinical trials before widespread adoption.

Despite these hurdles, the study by van Sloten and colleagues represents a quantum leap forward in cardiovascular epidemiology and precision health. By decoding the complex signatures of vascular aging within community populations, they have charted a novel pathway toward individualized risk prediction and tailored therapeutics. This research not only illuminates the hidden landscape of vascular aging but also charts a course toward healthier aging for millions globally.

In summary, the identification of distinct vascular aging clusters as robust predictors of incident cardiovascular events heralds a new era in cardiovascular medicine. Combining cutting-edge vascular phenotyping, advanced data analytics, and community-based cohort research, this landmark study challenges conventional risk assessment paradigms. It sets the stage for transforming how clinicians assess cardiovascular risk and personalize care based on nuanced vascular health signatures. Going forward, the integration of cluster-derived insights with emerging molecular and clinical data has the potential to revolutionize cardiovascular prevention and treatment on a global scale.

Van Sloten et al.’s contribution represents a beacon of hope in the quest to mitigate the global burden of cardiovascular disease through innovative science and patient-centered care. As the population ages and cardiovascular challenges intensify, the promise of cluster-based vascular aging evaluation holds the key to unlocking proactive strategies that preserve vascular integrity and extend healthy lifespans.

Subject of Research: Clusters of vascular aging manifestations and their role in predicting cardiovascular events in community populations.

Article Title: Clusters of vascular aging manifestations predict incident cardiovascular events in the community.

Article References:
van Sloten, T., Boutouyrie, P., Abouqateb, M. et al. Clusters of vascular aging manifestations predict incident cardiovascular events in the community. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70137-4

Image Credits: AI Generated